Use of autoprobiotics in the complex therapy of axial spondyloarthritis

Spondyloarthritis (SpA) is a group of chronic inflammatory diseases of the musculoskeletal system involving of the axial skeleton and extra-articular manifestations such as inflammatory bowel diseases. Some violations of the intestinal microbiome often occur during the course of spondyloarthritis. Also, intestinal dysbiosis can be enhanced by ongoing therapy. The aim of the study was to evaluate the effectiveness of combined therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and autoprobiotics supplementation.

SpA patients treated with NSAID were divided into two groups: group A which took autoprobiotic based on indigenous culture of Enterococcus faecium, and group S which took only Supra medium, which is the basis used for making of autoprobiotic. Reducing of pain intensity, dyspeptic phenomena were observed to a greater extent in group A compared to group S. PCRRT testing revealed no significant changes in intestinal microbiocenosis in patients with SpA, except of a decrease in the Lactobacillus population, which was restored only in group A. A feature of the changes in group S was a decrease in the total bacterial mass, amounts of Bacteroides, Faecalibacterium, Enterobacter and expansion of Methanobrevibacter population. The tendency to restore the quantitative content of Lactobacillus, correlating with a decrease of IL-10 concentration, was found only in group A.

In our study the effectiveness of enterococcal auprobiotic supplementation as an element of complex therapy of patient suffering from SpA has been proven. The use of an autoprobiotic leads to a decrease in the severity of the symptoms of the disease, the leveling of dyspeptic symptoms and microbiota disorders.

1. Sieper J, Poddubnyy D. Axial spondyloarthritis. The Lancet. 2017; 390(10089):73–84.

2. Mauro D, Simone D, Bucci L. Novel immune cell phenotypes in spondyloarthritis pathogenesis. Semin Immunopathol. 2021; 43:265–277.

3. So J, Tam L.-S. Gut Microbiome and Its Interaction with Immune System in Spondyloarthritis. Mi croorganisms. 2020; 8:1727–1741.

4. Aroldo R, Angelo F, Giuliana G. Gut inflammation in spondyloarthritis. Best Practice & Research Clinical Rheumatology. 2017; 31(6):863–876.

5. Galushko EA, Gordeev AV. Gut microbiome and spondyloarthritis. Experimental and clinical gastroenterology. 2019; 2:162. In Russian

6. Breban M, Tap J, Leboime A, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Annals of the rheumatic diseases. 2017; 76(9):1614–1622.

7. Tito R, Cypers H, Joossens M. Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis & rheumatology. 2017; 69(1):114–121.

8. Stoll M. Gut microbes, immunity, and spondyloarthritis. Clinical Immunology. 2015; 159(2):134–142.

9. Belkaid Y, Hand T. Role of the microbiota in immunity and inflammation. Cell. 2014; 157:121–141.

10. Cho J, Gregersen P. Genomics and the multifactorial nature of human autoimmune disease. The New England Journal of Medicine. 2011; 365:1612–1623.

11. Zawistowska-Rojek A, Tyski S. How to Improve Health with Biological Agents - Narrative Review. Nutrients. 2022; 14:1700.

12. Kedia S, Virmani S. Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial. Gut. 2022; 71:2401–2413.

13. Imdad A, Nicholson M, Tanner-Smith E, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews. 2018; 11(11):CD012774.

14. Olivieri I, Cantini F, Castiglione F. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmunity Reviews. 2014; 13(8):822–830.

15. Kragsnaes M, Kjeldsen J, Horn H. Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. Annals of the Rheumatic Diseases. 2021; 80:1158–1167.

16. Simanenkov VI, Suvorov AN, Solovieva OI, et al. A method for obtaining a personalized autoprobiotic product and a method for treating irritable bowel syndrome using this product. Patent for invention # 2546253, 04.25.2013. In Russian

17. Suvorov AN, Simanenkov VI, Sundukova ZR, Ermolenko EI, Tsapieva AN, Donets VN, Solovieva OI. Patent for invention # 2460778, 12.30.2010. In Russian

18. Suvorov A, Karaseva A, Kotyleva M, et al. Autoprobiotics as an Approach for Restoration of Personalised Microbiota. Frontiers in microbiology. 2018; 12(9):1869.

19. Solovyova O, Simanenkov V, Suvorov A, et al. The use of probiotics and autoprobiotics in the treatment of irritable bowel syndrome. Experimental and clinical gastroenterology. 2017; 7(143):115–120.

20. Maseda D, Ricciotti E. NSAID-Gut Microbiota Interactions. Frontiers in Pharmacology. 2020; 11:1153.

21. Ermolenko EI, Milyukhina IV, Tsapieva AN, Alekhina GG, Istomin AS, Gracheva EV, Kotyleva MP, Suvorov AN. Method for reducing the severity of nonmotor symptoms in patients suffering from Parkinson’s disease. Patent # 2734718, 10.22.2020. In Russian

22. Schaeverbeke T, Truchetet ME, Richez C. Gut metagenome and spondyloarthritis. Joint Bone Spine. 2013; 80(4):349–52.

23. Erdes ShF, Volnukhin EV, Galushko EA. Treatment of patients with ankylosing spondylitis in the real practice of a rheumatologist in Russia. Scientific and practical rheumatology. 2013; 51(1):15–20. In Russian

24. Xiao X, Nakatsu G, Jin Y, et al. Gut Microbiota Mediates Protection Against Enteropathy Induced by Indomethacin. Scientific Reports. 2017; 7:40317.

25. Syer SD, Blackler RW, Martin R, et al. NSAID enteropathy and bacteria: a complicated relationship. Journal of Gastroenterology. 2015; 50(4):387–393.

26. Colucci R, Pellegrini C, Fornai M, et al. Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. Frontiers in Pharmacology. 2018; 9:1340:1340.

27. Montrose DC, Zhou XK, McNally EM, et al. Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden. Cancer prevention research (Philadelphia, Pa.). 2016; 9:721–731.

28. Edogawa S, Peters SA, Jenkins GD, et al. Sex differences in NSAID-induced perturbationof human intestinal barrier function and microbiota. FASEB Journal. 2018; 32(12): 6615–6625.

29. Kim JE, Sharma A, Sharma G, et al. Lactobacillus pentosus Modulates Immune Response by Inducing IL-10 Producing Tr1 Cells. Immune Network. 2019; 19(6):e39.

30. Seo M, Heo J, Yoon J, et al. Methanobrevibacter attenuation via probiotic intervention reduces flatulence in adult human: A non-randomised paired-design clinical trial of efficacy. PLoS One. 2017; 12(9):e0184547.